These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

691 related articles for article (PubMed ID: 29723601)

  • 41. Identification of somatic TERT promoter mutations in familial nonmedullary thyroid carcinomas.
    Marques IJ; Moura MM; Cabrera R; Pinto AE; Simões-Pereira J; Santos C; Menezes FD; Montezuma D; Henrique R; Rodrigues Teixeira M; Leite V; Cavaco BM
    Clin Endocrinol (Oxf); 2017 Oct; 87(4):394-399. PubMed ID: 28502101
    [TBL] [Abstract][Full Text] [Related]  

  • 42. DICER1 Mutations Occur in More Than One-Third of Follicular-Patterned Pediatric Papillary Thyroid Carcinomas and Correlate with a Low-Risk Disease and Female Gender Predilection.
    Onder S; Mete O; Yilmaz I; Bayram A; Bagbudar S; Altay AY; Issin G; Terzi NK; Iscan Y; Sormaz IC; Tunca F; Senyurek YG; Yegen G
    Endocr Pathol; 2022 Dec; 33(4):437-445. PubMed ID: 36251117
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differentiating BRAF V600E- and RAS-like alterations in encapsulated follicular patterned tumors through histologic features: a validation study.
    Kim C; Agarwal S; Bychkov A; Hang JF; Harahap AS; Hirokawa M; Kakudo K; Keelawat S; Liu CY; Liu Z; Nguyen TP; Rana C; Vuong HG; Zhu Y; Jung CK
    Virchows Arch; 2024 Apr; 484(4):645-656. PubMed ID: 38366204
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Discriminating Interpatient Variabilities of RAS Gene Variants for Precision Detection of Thyroid Cancer.
    Fu G; Chazen RS; MacMillan C; Witterick IJ
    JAMA Netw Open; 2024 May; 7(5):e2411919. PubMed ID: 38758552
    [TBL] [Abstract][Full Text] [Related]  

  • 45. From nodule to differentiated thyroid carcinoma: contributions of molecular analysis in 2012.
    Albarel F; Conte-Devolx B; Oliver C
    Ann Endocrinol (Paris); 2012 Jun; 73(3):155-64. PubMed ID: 22503804
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The mutational analysis in the diagnostic work-up of thyroid nodules: the real impact in a center with large experience in thyroid cytopathology.
    Macerola E; Rago T; Proietti A; Basolo F; Vitti P
    J Endocrinol Invest; 2019 Feb; 42(2):157-166. PubMed ID: 29704233
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Role of gene expression profiling in defining indeterminate thyroid nodules in addition to BRAF analysis.
    Borrelli N; Ugolini C; Giannini R; Antonelli A; Giordano M; Sensi E; Torregrossa L; Fallahi P; Miccoli P; Basolo F
    Cancer Cytopathol; 2016 May; 124(5):340-9. PubMed ID: 26749005
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Classification of Thyroid Tumors Based on DNA Methylation Patterns.
    Marczyk VR; Recamonde-Mendoza M; Maia AL; Goemann IM
    Thyroid; 2023 Sep; 33(9):1090-1099. PubMed ID: 37392021
    [No Abstract]   [Full Text] [Related]  

  • 49. Somatic Mutations in the BRAF, KRAS, NRAS, EIF1AX, and TERT Genes: Diagnostic Value in Thyroid Neoplasms.
    Kachko VA; Vanushko VE; Platonova NM; Abrosimov AY; Mel'nichenko GA
    Bull Exp Biol Med; 2020 Sep; 169(5):669-672. PubMed ID: 32990852
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MicroRNA expression profiling of RAS-mutant thyroid tumors with follicular architecture: microRNA signatures to discriminate benign from malignant lesions.
    Macerola E; Poma AM; Vignali P; Proietti A; Torregrossa L; Ugolini C; Basolo A; Matrone A; Elisei R; Santini F; Basolo F
    J Endocrinol Invest; 2023 Aug; 46(8):1651-1662. PubMed ID: 36749451
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic significance of TERT promoter and BRAF mutations in TIR-4 and TIR-5 thyroid cytology.
    Censi S; Barollo S; Grespan E; Watutantrige-Fernando S; Manso J; Iacobone M; Casal Ide E; Galuppini F; Fassina A; Bertazza L; Vianello F; Pennelli G; Mian C
    Eur J Endocrinol; 2019 Jul; 181(1):1-11. PubMed ID: 31042674
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns.
    Rivera M; Ricarte-Filho J; Knauf J; Shaha A; Tuttle M; Fagin JA; Ghossein RA
    Mod Pathol; 2010 Sep; 23(9):1191-200. PubMed ID: 20526288
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features Accounts for More Than Half of "Carcinomas" Harboring RAS Mutations.
    Paulson VA; Shivdasani P; Angell TE; Cibas ES; Krane JF; Lindeman NI; Alexander EK; Barletta JA
    Thyroid; 2017 Apr; 27(4):506-511. PubMed ID: 28114855
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Laser capture microdissection is a valuable tool in the preoperative molecular screening of follicular lesions of the thyroid: an institutional experience.
    Bongiovanni M; Molinari F; Eszlinger M; Paschke R; Barizzi J; Merlo E; Giovanella L; Fasolini F; Cattaneo F; Ramelli F; Mazzucchelli L; Frattini M
    Cytopathology; 2015 Oct; 26(5):288-96. PubMed ID: 25487739
    [TBL] [Abstract][Full Text] [Related]  

  • 55. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.
    Nikiforova MN; Lynch RA; Biddinger PW; Alexander EK; Dorn GW; Tallini G; Kroll TG; Nikiforov YE
    J Clin Endocrinol Metab; 2003 May; 88(5):2318-26. PubMed ID: 12727991
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
    Landa I; Ganly I; Chan TA; Mitsutake N; Matsuse M; Ibrahimpasic T; Ghossein RA; Fagin JA
    J Clin Endocrinol Metab; 2013 Sep; 98(9):E1562-6. PubMed ID: 23833040
    [TBL] [Abstract][Full Text] [Related]  

  • 57. NRAS codon 61 mutation is associated with distant metastasis in patients with follicular thyroid carcinoma.
    Jang EK; Song DE; Sim SY; Kwon H; Choi YM; Jeon MJ; Han JM; Kim WG; Kim TY; Shong YK; Kim WB
    Thyroid; 2014 Aug; 24(8):1275-81. PubMed ID: 24820091
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mutational burdens and evolutionary ages of thyroid follicular adenoma are comparable to those of follicular carcinoma.
    Jung SH; Kim MS; Jung CK; Park HC; Kim SY; Liu J; Bae JS; Lee SH; Kim TM; Lee SH; Chung YJ
    Oncotarget; 2016 Oct; 7(43):69638-69648. PubMed ID: 27626165
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Metastatic-prone telomerase reverse transcriptase (TERT) promoter and v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutated tall cell variant of papillary thyroid carcinoma arising in ectopic thyroid tissue: A case report.
    Stenman A; Koman A; Ihre-Lundgren C; Juhlin CC
    Medicine (Baltimore); 2021 Jan; 100(2):e24237. PubMed ID: 33466206
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The histologic outcomes of indeterminate thyroid nodules with rat sarcoma mutations: A case series.
    Jones M; Abendano DG; Turner M; Sullivan C; Reyes MCD
    Diagn Cytopathol; 2023 Dec; 51(12):E332-E337. PubMed ID: 37583345
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.